Otonomy up 6% on hearing loss data


The American neurotology company Otonomy (Nasdaq: OTIC) closed up 6% on Wednesday after reporting the first positive results of the phase IIa clinical trial of OTO-413 in subjects with hearing loss.

The study showed that a single intratympanic injection of 0.3 mg of OTO-413, an extended exposure formulation of brain-derived neurotrophic factor (BDNF), provided clinically significant therapeutic benefit over placebo on several speech-in-noise hearing tests…

This article is accessible to registered users, to continue reading, please register for free. A free trial will give you access to exclusive features, interviews, summaries and commentary from the sharpest minds in the pharma and biotech space for one week. If you are already a registered user, please login. If your trial period is over, you can register here.

Try before you buy

• All the news that moves the needle in pharma and biotech.
• Exclusive features, podcasts, interviews, data analysis and commentary from our global network of life science journalists.
• Receive The Pharma Letter daily newsletter, free forever.

Become a subscriber

• Unfettered access to top pharmaceutical and biotechnology industry news, commentary and analysis.
• Updates on clinical trials, conferences, mergers and acquisitions, licensing, financing, regulatory, patent and legal, executive appointments, business strategy and financial results.
• Daily roundup of key events in pharma and biotechnology.
• In-depth monthly briefings on board appointments and M&A news.
• Choose between an economical annual plan or a flexible monthly subscription.


Comments are closed.